Shorter radiation plus immunotherapy may improve rectal cancer outcomes

NCT ID NCT07551479

First seen May 01, 2026 · Last updated May 09, 2026 · Updated 3 times

Summary

This study tests a new treatment approach for people with high-risk locally advanced rectal cancer. It compares short-course radiation followed by chemotherapy plus an immunotherapy drug (serplulimab) against the standard long-course chemoradiation followed by chemotherapy. The goal is to see if the new approach improves the chance of being cancer-free after 3 years and helps more patients avoid surgery. About 612 participants will be enrolled across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.